[go: up one dir, main page]

AR122036A2 - STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A - Google Patents

STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A

Info

Publication number
AR122036A2
AR122036A2 ARP210101255A ARP210101255A AR122036A2 AR 122036 A2 AR122036 A2 AR 122036A2 AR P210101255 A ARP210101255 A AR P210101255A AR P210101255 A ARP210101255 A AR P210101255A AR 122036 A2 AR122036 A2 AR 122036A2
Authority
AR
Argentina
Prior art keywords
arisulfatase
administration
pharmaceutical compositions
stable pharmaceutical
intratecal
Prior art date
Application number
ARP210101255A
Other languages
Spanish (es)
Inventor
Nazila Salamat-Miller
Katherine Taylor
Paul Campolieto
Zahra Shahrokh
Jing Pan
Lawrence Charnas
Teresa Leah Wright
Pericles Calias
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of AR122036A2 publication Critical patent/AR122036A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a la administración intratecal de enzimas lisosomales para el tratamiento eficaz de enfermedades de almacenamiento lisosomal. En algunas formas de realización, la invención proporciona formulaciones estables para la administración IT de Arilsulfatasa A. Reivindicación 1: Un envase caracterizado porque comprende una forma de dosificación unitaria de una formulación estable que comprende una proteína arilsulfatasa A (ASA) recombinante presente en una concentración que varía de aproximadamente 5 - 100 mg/ml.The present invention relates to the intrathecal administration of lysosomal enzymes for the effective treatment of lysosomal storage diseases. In some embodiments, the invention provides stable formulations for IT administration of Arylsulfatase A. Claim 1: A container characterized in that it comprises a unit dosage form of a stable formulation comprising a recombinant arylsulfatase A (ASA) protein present in a concentration ranging from about 5-100 mg/ml.

ARP210101255A 2010-06-25 2021-05-07 STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A AR122036A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25

Publications (1)

Publication Number Publication Date
AR122036A2 true AR122036A2 (en) 2022-08-03

Family

ID=75905105

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP190102272A AR115942A2 (en) 2010-06-25 2019-08-09 STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A AND CONTAINING CONTAINERS
ARP210101255A AR122036A2 (en) 2010-06-25 2021-05-07 STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A
ARP210103195A AR124100A2 (en) 2010-06-25 2021-11-18 PHARMACEUTICAL COMPOSITIONS FOR THE INTRATHECAL ADMINISTRATION OF LYSOSOMIC ENZYMES
ARP210103544A AR124399A2 (en) 2010-06-25 2021-12-16 STABLE FORMULATIONS FOR THE INTRATHECAL ADMINISTRATION OF IDURANATE-2-SULFATASE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP190102272A AR115942A2 (en) 2010-06-25 2019-08-09 STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A AND CONTAINING CONTAINERS

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP210103195A AR124100A2 (en) 2010-06-25 2021-11-18 PHARMACEUTICAL COMPOSITIONS FOR THE INTRATHECAL ADMINISTRATION OF LYSOSOMIC ENZYMES
ARP210103544A AR124399A2 (en) 2010-06-25 2021-12-16 STABLE FORMULATIONS FOR THE INTRATHECAL ADMINISTRATION OF IDURANATE-2-SULFATASE

Country Status (1)

Country Link
AR (4) AR115942A2 (en)

Also Published As

Publication number Publication date
AR124399A2 (en) 2023-03-22
AR115942A2 (en) 2021-03-17
AR124100A2 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
CY1124703T1 (en) METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONIC-2-SULFATASE
CY1124910T1 (en) METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLOSULFATASE A
EA201492021A1 (en) ANTI-COMPOSITION
EA201491285A1 (en) IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID
PE20180130A1 (en) COMPOSITIONS AND METHODS FOR SUPPLYING THE CENTRAL NERVOUS SYSTEM OF ARYLSULFATASE A
CO6700848A2 (en) Enteric coated pancreliplase formulations, low intensity
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
CO6680698A2 (en) Dexmedetomidine premix formulation
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
GT200700034A (en) PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
WO2011163651A3 (en) METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
TR200900878A2 (en) Pharmaceutical formulations combined in a single dosage form
AR091530A1 (en) PHARMACEUTICAL FORMULATION LIQUID OF AN ANTIBODY AND ACETATE
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
WO2013096899A3 (en) Stable formulations for cns delivery of arylsulfatase a
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
BR112015012497A8 (en) pharmaceutical combinations and compositions, their uses, combined preparation, and commercial packaging
UY32600A (en) FORMULATION IN LIPIDS OF AN APOPTOSIS PROMOTER
EA201390950A1 (en) HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID
GT200800235A (en) FORMULATION OF LIQUID MEDICINAL PRODUCT
AR122036A2 (en) STABLE PHARMACEUTICAL COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF ARISULFATASE A
EA201500128A1 (en) PEDIATRIC LIQUID COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING NEPATUTANEAN
TR200900880A2 (en) Pharmaceutical compositions combined in a single dosage form.
UY31212A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT
TNSN06335A1 (en) Novel stable oral risperidone solution

Legal Events

Date Code Title Description
FC Refusal